Holen Sie sich die Stockscreener-App
8.80
3.17%
0.27
Handel nachbörslich:
8.97
0.17
+1.93%
Schlusskurs vom Vortag:
$8.53
Offen:
$8.53
24-Stunden-Volumen:
560.01K
Relative Volume:
0.59
Marktkapitalisierung:
$454.19M
Einnahmen:
$170.44M
Nettoeinkommen (Verlust:
$-193.88M
KGV:
-2.3441
EPS:
-3.7541
Netto-Cashflow:
$-126.38M
1W Leistung:
+13.26%
1M Leistung:
+1.73%
6M Leistung:
-17.68%
1J Leistung:
+39.90%
1-Tages-Spanne:
$8.5065
$9.07
1-Wochen-Bereich:
$8.04
$9.07
52-Wochen-Spanne:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.80 | 440.26M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Book value per share of REGENXBIO, Inc. – SWB:RB0 - TradingView
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Metachromatic Leukodystrophy Treatment Market to Reach US$ - openPR.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPC - GlobeNewswire Inc.
CapEx per share of REGENXBIO, Inc. – SWB:RB0 - TradingView
Tangible book value per share of REGENXBIO, Inc. – SWB:RB0 - TradingView
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Eagle-Tribune
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RGNX PE Ratio & Valuation, Is RGNX Overvalued - Intellectia AI
RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
REGENXBIO, Inc. Class Action ReminderRobbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights - Sahm
REGENXBIO: CEO Makes Major Sale During Legal Battle While Investors Split - Bitget
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - ChartMill
REGENXBIO (RGNX) proxy: directors, PwC ratification, option-exchange votes - stocktitan.net
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Australia
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-04-02 | RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 | NDAQ:RGNX | Press Release - Stockhouse
ROSEN, A TOP RANKED INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure ... - Bluefield Daily Telegraph
RGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP - Morningstar
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Trading Systems Reacting to (RGNX) Volatility - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - ChartMill
User - The Chronicle-Journal
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
RGNX Shareholder Alert: Investors With Losses May Seek to Lead t - GuruFocus
REGENXBIO joins CureDuchenne community event to advance therapies for Duchenne - Traders Union
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today! - accessnewswire.com
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Inve - GuruFocus
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - marketscreener.com
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Vanguard (RGNX) disaggregates holdings; reports 0 shares after realignment - Stock Titan
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO ... - Bluefield Daily Telegraph
RGNX Shareholder Alert: Investors With Losses May Seek to - globenewswire.com
RGNX Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
REGENXBIO Inc. $RGNX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. - globenewswire.com
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - prnewswire.com
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):